2024 Pharm Exec Top 50 Companies
Jun 14, 2024 · As we noted in last year’s report, Novo Nordisk and Eli Lilly, competing in the lucrative GLP-1 receptor agonist space that, of late, has captivated the US and beyond in weight loss, are knocking loudly on the top-10 door.Both companies, who own the highest market caps, respectively, in pharma, turned in massive growth in our latest Pharma 50.
Pharmaceutical Executive
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
Financial Times Global Pharma and Biotech Summit: The Impact of …
Nov 7, 2024 · Donald Trump’s victory in the 2024 US presidential election is sure to have an impact on the pharmaceutical industry. During a panel at the Financial Times’ 2024 Global Pharma and Biotech Summit, the following speakers met to discuss the outcome of the election and the impact it may have on the industry: Lauren Fedor, US political correspondent and …
Understanding IDNs and What They Mean to the Pharmaceutical …
Aug 2, 2024 · Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, president and chief revenue officer at EVERSANA, spoke with Pharmaceutical Executive about the ways that commercialization teams are working with these networks to bring drugs to markets.
Four for 2024: Predictions for the Future of Pharmacy Technology
Jan 9, 2024 · What does the future hold for pharmacy technology? It’s a question we’re asking across the industry, but as a pharmacist who works to improve technology to make it easier and safer to help care for patients, I'm sharing four predictions for 2024.
2023 Pharm Exec Top 50 Companies
Jun 10, 2023 · Movers and shakers. As mentioned, Pfizer and AbbVie captured the top two spots again in the Pharma 50—the latter, notably, expected to maintain its solid momentum, even with Humira’s patent expiration this year, thanks to reinforcements Skyrizi for psoriasis (up 75.7% in sales in 2022 to $5.2 billion) and JAK inhibitor Rinvoq (with seven approvals so far, including …
2024Finalists - pharmexec.com
Agency: Avant Healthcare Pharmaceutical Company: UCB Campaign: Make HStory (US HCP Campaign) Agency: ClinicalMind Pharmaceutical Company: TruElastin Laboratories, Inc. Campaign: Pushing the limits of aesthetics Agency: MedTrix Healthcare Pharmaceutical Company: Allergan Medical Institute, An Abbvie Company Campaign: The Virtual Patient …
Amgen's Novel Weight Loss Drug Shows Potential for Longer …
Feb 6, 2024 · Amgen’s novel weight loss drug candidate maridebart cafraglutide (MariTide) showed significant promise in a Phase I trial (NCT04478708), with data suggesting longer lasting and durable reductions in body weight compared with the popular glucagon-like peptide (GLP)-1 agonists currently on the market—Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s …
Podcasts - pharmexec.com
In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable …
Pharmaceutical Executive - PharmExec
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.